A trafficking regulatory subnetwork governs α<sub>V</sub>β<sub>6</sub> integrin-HER2 cross-talk to control breast cancer invasion and drug resistance.

Maldonado, Horacio; Dreger, Marcel; Bedgood, Lara D; Kyriakou, Theano; Wolanska, Katarzyna I; Rigby, Megan E; Marotta, Valeria E; Webster, Justine M et al. · Sci Adv · 2024

basic_science · Level V

Where this comes from

Abstract

HER2 and α<sub>V</sub>β<sub>6</sub> integrin are independent predictors of breast cancer survival and metastasis. We identify an α<sub>V</sub>β<sub>6</sub>/HER2 cross-talk mechanism driving invasion, which is dysregulated in drug-resistant HER2+ breast cancer cells. Proteomic analyses reveal ligand-bound α<sub>V</sub>β<sub>6</sub> recruits HER2 and a trafficking subnetwork, comprising guanosine triphosphatases RAB5 and RAB7A and the Rab regulator guanine nucleotide dissociation inhibitor 2 (GDI2). The RAB5/RAB7A/GDI2 functional module mediates direct cross-talk between α<sub>V</sub>β<sub>6</sub> and HER2, affecting receptor trafficking and signaling. Acute exposure to trastuzumab increases recruitment of the subnetwork to α<sub>V</sub>β<sub>6</sub>, but trastuzumab resistance decouples GDI2 recruitment. GDI2, RAB5, and RAB7A cooperate to regulate migration and transforming growth factor-β activation to promote invasion. However, these mechanisms are dysregulated in trastuzumab-resistant cells. In patients, <i>RAB5A</i>, <i>RAB7A</i>, and <i>GDI2</i> expression correlates with patient survival and α<sub>V</sub>β<sub>6</sub> expression predicts relapse following trastuzumab treatment. Thus, the RAB5/RAB7A/GDI2 subnetwork regulates α<sub>V</sub>β<sub>6</sub>-HER2 cross-talk to drive breast cancer invasion but is subverted in trastuzumab-resistant cells to drive α<sub>V</sub>β<sub>6</sub>-independent and HER2-independent tumor progression.

Medical subject headings